Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Qiagen N.V. Common Shares (NY: QGEN )

42.15 -0.91 (-2.11%)
Streaming Delayed Price Updated: 12:49 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 7 Next >
QIAGEN N.V. to release results for Q4 2021 and Full-Year of 2021
From QIAGEN N.V.
Via Business Wire
QIAGEN Launches QIAwave Portfolio of Environmentally Friendly Products
From QIAGEN N.V.
Via Business Wire
What Does Qiagen's Debt Look Like?
Over the past three months, shares of Qiagen (NYSE:QGEN) moved lower by 5.06%. Before we understand the importance of debt, let us look at how much debt Qiagen has. Qiagen... 
Via Benzinga
QIAGEN expands QIAstat-Dx syndromic testing menu and announces launch plans for new QIAstat-Dx Rise higher-throughput version
From QIAGEN N.V.
Via Business Wire
QIAGEN Strengthens Growing Portfolio of Applications for Its Digital PCR Platform QIAcuity With New Collaborations
From QIAGEN N.V.
Via Business Wire
QIAGEN Expands QuantiFERON Portfolio in the Fight Against TB
From QIAGEN N.V.
Via Business Wire
Free COVID Tests: What Stocks Will Benefit?
The government hasn’t announced yet what company or companies it will be buying from, but there are several businesses involved in producing these kits. 
Via Talk Markets
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug... 
Via Benzinga
Exposures COVID-19 Product Safety
QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
From QIAGEN N.V.
Via Business Wire
QIAGEN Launches CE-marked Version of QuantiFERON® SARS-CoV-2 to Assess T-cell Response to COVID-19
From QIAGEN N.V.
Via Business Wire
QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON®-TB Gold Plus assay on LIAISON® XS
From QIAGEN N.V.
Via Business Wire
Qiagen Says Its COVID-19 PCR Tests Can Detect The New South African Variant
Qiagen N.V. (NYSE:QGEN) announced that its polymerase c... 
Via Benzinga
Exposures COVID-19
Rising Test Accuracy Standards Needed as On-Site Demand for Covid-19 Testing Increases
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 9, 2021 – USA News Group – After the launch of US President Joe Biden’s pushing of mandatory vaccination/testing in the... 
Via FinancialNewsMedia
Exposures COVID-19
QIAGEN Commits to Reduce Carbon Emissions by Setting Science-Based Target to Reach Net Zero by 2050
From QIAGEN N.V.
Via Business Wire
Qiagen, Becton Dickinson Settle Patent Infringement Lawsuit For $53M
Qiagen N.V. (NYSE: QGEN) settled with Becton Dickinson & Co (NYSE: BDX) a patent infringement lawsuit related to Qiagen's NeuMoDx 96 and NeuMoDx... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
QIAGEN and BD Settle Patent Infringement Lawsuit
From QIAGEN N.V.
Via Business Wire
Qiagen NV (QGEN) Q3 2021 Earnings Call Transcript
QGEN earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Qiagen Clocks 17% Increase In Non-COVID Product Sales; Raises FY21 Guidance
Qiagen N.V.'s (NYSE: QGEN) Q3 revenues grew 11% Y/Y to $535 million (+10% at constant exchange rates), well above the consensus of $434.97 million. Non-COVID... 
Via Benzinga
QIAGEN Reports Strong Results for Third Quarter and First Nine Months Of 2021
From QIAGEN N.V.
Via Business Wire
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
Exposures Pension
QIAGEN expands QIAstat-Dx testing menu with respiratory four-plex panel that differentiates between flu, RSV and SARS-CoV-2
From QIAGEN N.V.
Via Business Wire
QIAGEN Strengthens UK Footprint With Move to New Manchester Facilities
From QIAGEN N.V.
Via Business Wire
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
QIAGEN N.V. to Release Results for Q3 2021 and First Nine Months of 2021
From QIAGEN N.V.
Via Business Wire
QIAGEN Launches Novel QIAreach QuantiFERON-TB Tuberculosis Test for High-Burden Regions
From QIAGEN N.V.
Via Business Wire
Qiagen Secures DoD Contract To Boost Production Capacity For NeuMoDx
Qiagen NV (NYSE: QGEN) won a U.S. government contract to increase the production capacity for consumables used on its NeuMoDx 96 and 288 integrated PCR testing... 
Via Benzinga
QIAGEN Receives U.S. Department of Defense Contract to Further Expand Production Capacity for NeuMoDx
From QIAGEN N.V.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX: 
Via Benzinga
Big Changes Coming to Covid Testing in Response to Rising Demand Under Latest Mandates
Via FinancialNewsMedia
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.